Jack Ziegler
Cardiovascular Disease · Hobart, INNPI 1609876861
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,682 and has fallen 98.7% since, to $22 in 2023.
Across 324 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$881
- Johnson & Johnson$706
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$493
- Amgen$415
- AstraZeneca$404
- Boehringer Ingelheim$329
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,029100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 63 | $881 |
| Johnson & Johnson | 45 | $706 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 30 | $493 |
| Amgen | 26 | $415 |
| AstraZeneca | 29 | $404 |
| Boehringer Ingelheim | 21 | $329 |
| Sanofi-aventis U.S. LLC | 18 | $253 |
| Esperion Therapeutics, Inc. | 11 | $193 |
| Lundbeck LLC | 10 | $182 |
| Pfizer | 13 | $175 |
| Alnylam Pharmaceuticals Inc. | 6 | $145 |
| Chiesi USA, Inc. | 9 | $135 |
| Merck | 7 | $113 |
| Abbott | 4 | $83 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $68 |
| Amarin Pharma, Inc. | 5 | $66 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Gilead | 4 | $52 |
| Novo Nordisk | 2 | $45 |
| Vifor Pharma, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Cardiovascular Systems Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| AbbVie | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Abiomed | 1 | $14 |
| Boston Scientific | 1 | $11 |
How this compares
$5,038 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $1,004 |
| ClopidogrelClopidogrel Bisulfate | 13 | $179 |
| Amlodipine Besylate | 13 | $56 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Hobart
- Anas SafadiHobart$295K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.